{"result": "Here is a comprehensive summary of the data:\n\n\"Im YH is a researcher and author who has been involved in multiple studies related to breast cancer. Specifically, Im YH has conducted research on adjuvant capecitabine for breast cancer after preoperative chemotherapy, as well as studies on HER2-positive localized breast cancer. Additionally, Im YH has studied neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer. Furthermore, Im YH has authored studies on adjuvant capecitabine for breast cancer after preoperative chemotherapy, neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer, and pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. Im YH's research focuses on understanding and treating various types of breast cancer, including HER2-positive breast cancer, and has contributed to the development of new treatments and therapies for this disease.\"", "input": "\nYou are a helpful assistant responsible for generating a comprehensive summary of the data provided below.\nGiven one or two entities, and a list of descriptions, all related to the same entity or group of entities.\nPlease concatenate all of these into a single, comprehensive description. Make sure to include information collected from all the descriptions.\nIf the provided descriptions are contradictory, please resolve the contradictions and provide a single, coherent summary.\nMake sure it is written in third person, and include the entity names so we the have full context.\n\n#######\n-Data-\nEntities: \"\\\"IM YH\\\"\"\nDescription List: [\"\\\"Im YH is a researcher involved in a study on adjuvant capecitabine for breast cancer after preoperative chemotherapy.\\\"\", \"\\\"Im YH is a researcher involved in multiple studies on breast cancer and HER2-positive localized breast cancer.\\\"\", \"\\\"Im YH is a researcher involved in the study of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer.\\\"\", \"\\\"Im YH is an author of a study on adjuvant Capecitabine for breast cancer after preoperative chemotherapy.\\\"\", \"\\\"Im YH is an author of a study on neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer.\\\"\", \"\\\"Im YH is an author of a study on pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.\\\"\"]\n#######\nOutput:\n", "parameters": {"model": "llama3-8b-8192", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 500, "n": null}}